Stock analysts at Barclays began coverage on shares of Nurix Therapeutics (NASDAQ:NRIX – Get Rating) in a research report issued to clients and investors on Thursday, The Fly reports. The brokerage set an “overweight” rating and a $20.00 price target on the stock. Barclays‘s target price suggests a potential upside of 133.64% from the company’s current price.
Other research analysts also recently issued reports about the company. HC Wainwright restated a “buy” rating and issued a $53.00 price target on shares of Nurix Therapeutics in a research note on Friday, February 10th. SVB Leerink decreased their price objective on Nurix Therapeutics from $37.00 to $28.00 and set an “outperform” rating for the company in a report on Tuesday, December 13th. Stifel Nicolaus cut their target price on Nurix Therapeutics from $37.00 to $31.00 and set a “buy” rating on the stock in a research note on Tuesday, February 14th. Needham & Company LLC dropped their price target on Nurix Therapeutics from $32.00 to $31.00 and set a “buy” rating on the stock in a research note on Friday, February 10th. Finally, Royal Bank of Canada decreased their target price on Nurix Therapeutics from $39.00 to $30.00 and set an “outperform” rating for the company in a report on Friday, February 10th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $29.75.
Nurix Therapeutics Stock Performance
Shares of NASDAQ:NRIX opened at $8.56 on Thursday. Nurix Therapeutics has a fifty-two week low of $7.52 and a fifty-two week high of $19.91. The firm has a market cap of $404.63 million, a price-to-earnings ratio of -2.29 and a beta of 1.72. The business has a 50-day simple moving average of $10.85 and a two-hundred day simple moving average of $12.22.
Hedge Funds Weigh In On Nurix Therapeutics
Nurix Therapeutics Company Profile
Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
- Get a free copy of the StockNews.com research report on Nurix Therapeutics (NRIX)
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
- How to Buy High Yielding Dividend Stocks
- Oracle Has Spoken: Shares Fall 5%
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.